复方丹参滴丸对促红细胞生成素相关性高血压及高黏滞状态的影响

目的观察复方丹参滴丸对促红细胞生成素（EPO）相关性高血压及高黏滞状态的影响。方法46例维持性血液透析患者随机分为两组，每组23例，治疗组在EPO治疗基础上加用复方丹参滴丸10粒，每日三次，连服16周。观察两组患者治疗前后血红蛋白（Hb）、红细胞比容（Hct）、红细胞计数（RBC）、血液流变学、EPO相关性高血压、透析器凝血、降压药、肝素用量等指标的变化。结果16周后，两组贫血明显改善，平均Hb、Hct、RBC无明显差异；两组全血高切、低切黏度升高，治疗组升高幅度小于对照组，P〈0．05。治疗组透析器凝血、透析相关性高血压、心绞痛发生率较对照组明显减少，有统计学差异；对照组降压药使用种类及肝素用量明显增加，P〈0．05。两组纤维蛋白原含量、红细胞聚集指数无统计学差异。结论复方丹参滴丸具有减少EPO相关性高血压发生率、改善血液高黏滞状态、降低心绞痛发生率的作用。

The Effects of Fufang Danshen Diwan on Erythropoietin Associated Hypertension and Blood Viscosity

Objective To investigate the effects of Fufang Danshen Diwan（ Compound Danshen Drop Pills） on erythropoietin associated hypertension and blood viscosity in maintenance hemodialysis patients. Methods 46 patients were randomly divided into two groups control group was given erythropoietin; treatment group was given Fufang Danshen Diwan on the basis of erythropoietin. Patient＇ s Hb, Hct, RBC, blood viscosity, hypertension, hemoglutination were evaluated. Results After 16 weeks, whole blood high shear viscosity （5.94 ±0.78 vs 7.06 ±0.49, P 〈0.05） and low shear viscosity （ 12.13 ±3.34 vs 16.35±1.97, P 〈0.05） were increased significantly in both groups. Hb, Hct, RBC, red cell aggregation index and plasma fibrinogen were not significantly different in both groups. The rates of EPO associated hypertension （8.7% vs 47.8%, P 〈 0.01）, hemoglutination of dialyzer（ 8.7% vs 65.2%, P 〈 0. 001）, angina（21.7% vs 73.9%, P 〈 0. 001） were significantly lower in treatment group. The heparin used and the kinds of anti-hypertension medicine were increased significantly in control group. Conclusion Fufang Danshen Diwan can improve blood viscosity and reduce the rate of erythropoietin associated hypertension and angina.